103 results about "Bioactive compound" patented technology

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

Methods of making bioactive compound-loaded nanoparticles are provided. The methods harness naturally-occurring biopolymers to produce nanoparticles from raw plant materials. Methods include contacting plant-derived materials with alkaline solution with agitation to deprotonate the bioactive materials and biopolymers to form nanoparticles. In some forms, the methods contact the nanoparticle with an acid to re-protonate the components and more stable nanoparticles. The bioactive compounds can be extracted from raw plants and / or plant parts, including turmeric, ginger, clove, thyme, pepper, and rosemary. The bioactive compounds include curcumin, gingerols, shogaols, eugenol, thymol, carvacrol, capsaicin, and rosmarinic acid. Compositions and formulations containing bioactive-compound loaded nanoparticles are also provided.

The invention relates to the technical field of biological medicine, and discloses an application of an Aspisin small-molecule inhibitor in preparation of a medicine for preventing and / or treating diabetic nephropathy, and the Aspisin small-molecule inhibitor comprises ganoderic acid DM. The inhibitor ganoderic acid DM targeting Aspisin is screened from a bioactive compound library by combining high-throughput virtual drug screening with biological activity screening, it is found that ganoderic acid DM can be specifically combined with Aspisin and shows high affinity, and it is expected that an experimental basis is provided for clinical treatment and prevention of DKD and new drug research and development.

A method for treating a gastrointestinal condition includes preparing an aqueous extract of bioactive compound by adding dried green tea material to hot water and filtering the aqueous extract; adding a solution of an iron-containing compound to the filtered aqueous extract to form a complex or chelate of the bioactive compounds with iron; and drying the solution at a temperature between 80 to 150 degrees Fahrenheit to obtain a fine granular or powdered state.

Myotonic Dystrophy type 1 (DM1) is an inherited disease characterized by multi-systemic symptoms, particularly in skeletal muscles (progressive weakness and atrophy, myotonia). The inventors screened 7 500 bioactive compounds for their ability to improve the myogenic fusion and reduce the molecular hallmarks of DM1 skeletal muscle cells. The inventors found that five compounds, all inhibiting HDAC6, a cytoplasmic histone deacetylase, were effective at the micromolar range in normalizing the myogenic fusion, reducing the number of nuclear foci of mutant DMPK mRNA, decreasing the expression level of DMPK mRNA, restoring the splicing of several genes, and increasing the acetylation of SMAD3, a transcription factor involved in muscle development. The effects of HDAC6 inhibitors were observed both in immortalized and hiPSC-derived skeletal muscle cells from DM1 patients, and in different stages of differentiation. Thus, the present invention relates to the use of selective HDAC6 inhibitors for the treatment of DM1.

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

Provided herein are compositions comprising a particle comprising a library encoded bead (e.g., DEL bead) coated in a polymeric matrix forming a core-shell particle, wherein the core-shell particle is further inside a 3D tissue culture. Also provided herein are methods of making such particles, and methods of using such particles for drug discovery such as identification of bioactive compounds via high-throughput cellular activity-based phenotypic screens of DNA-encoded chemical library beads.

The present invention relates to a standardized plant extract of biomass from an in vitro culture of Brassica granatum, containing biologically active compounds and their primary and secondary metabolites, comprising, in% by weight: 4.0 to 6.0 organic acids, 0.5 to 1.5 fatty acids, 8.0 to 12.0 amino acids, 0.5 to 1.0 sterols, 3.0 to 6.0 free phenols, 45 to 55 sugars and 25.0 to 35.0 polyphenols, wherein the content of major mannose glycosides in the polyphenol fraction is 70-96%, making up 18%-35% of the total extract, and to compositions containing the standardized extract and glycerol and to methods for preparing standardized plant extracts. According to the method of the invention, along with the optimally selected steps, specific conditions, parameters such as temperature, duration, agitation, light, growth factors and the like, maximum volume productivity of the target substance and mannoside and stable productivity of in vitro plant cultures are achieved, and the method is a reliable and effective 24 / 7 continuous system for the production of NP.

This invention relates to the formula and process of making cookies based on sorghum flour (Sorghum bicolor L. Moench) with the addition of red ginger powder (Zingiber officinale var. rubrum) as a gluten-free functional food based on local Indonesian raw materials. The developed formula consists of sorghum flour as the main ingredient, red ginger powder, margarine, brown sugar, chicken eggs, and salt. This product inherently contains the bioactive compounds gingerol and shogaol from red ginger as natural added value, making it an alternative gluten-free cookie with functional value based on local resources.

The present invention provides a novel room-temperature extraction system and method for cannabis and hemp, utilizing custom membrane filtration to efficiently isolate cannabinoids, terpenes, and other bioactive compounds while reducing energy consumption. This multi-stage system begins with a custom milling machine that preprocesses biomass by separating non-target components, such as cellulose-rich stalks, to improve extraction efficiency. The core extraction process employs a series of custom membranes designed to selectively filter cannabinoids and terpenes, minimizing impurities without the need for traditional sub-zero cooling. Each membrane stage incorporates solvent recovery to recycle ethanol, reducing waste and operational costs. In the final stage, a custom concentrator removes residual ethanol, decarboxylates THCa to THC, and crystallizes sugars to prevent downstream clogging. This room-temperature extraction system significantly enhances yield, purity, and sustainability, making it a scalable and cost-effective solution for cannabis and hemp processing industries, as well as applicable for pharmaceutical and nutraceutical uses.

A family of bioactive compounds identified in self-resolving inflammatory exudates is disclosed. The compounds give UV chromophores characteristic of a conjugated triene double bond system coupled to an auxochrome allylic to the triene. Further elucidation of the compounds reveals that they have a resolvin backbone conjugated to a peptide or amino acid moiety via an auxochrome. In some embodiments the auxochrome is sulfur. However, the auxochrome may be NH, CH2 or O. The compounds have potent bioactivity, in vitro, and, in vivo, including promoting resolution of infection, stimulating macrophage phagocytosis of bacteria; protecting tissues from neutrophil mediated damage, promoting tissue repair and regeneration and preventing or limiting second organ reflow / reperfusion damage.

The invention discloses a chiral oxazoline ligand containing an indole skeleton as well as a synthesis method and application of the chiral oxazoline ligand. The chiral ligand has a structure as shown in a formula 1, and R1 is selected from one of alkyl, substituted alkyl, aryl and substituted aryl. The chiral oxazoline ligand of the indole skeleton can realize high-enantioselectivity Friedel-Crafts reaction of an indole skeleton compound, the reaction is one of important carbon-carbon bond forming methods in organic synthesis, and a chiral indole derivative can be efficiently generated; the chiral indole derivative has important application in synthesis of natural products and bioactive compounds. In addition, raw materials used for preparing the compound are cheap and easy to obtain, the synthesis route is short, the related reaction is a basic organic chemical reaction, the process is simple and convenient, the product is easy to separate and purify, and the method is suitable for large-scale synthesis.

The present invention relates to a system for the release of bioactive compounds comprising biodegradable colloidal particles with an average size less than 500 nm, where the biodegradable colloidal particles comprise an anionic polysaccharide and a cationic polysaccharide. Furthermore, its method of extraction includes: (a) estimating the stoichiometric charge ratio between an anionic polysaccharide, and a cationic polysaccharide; (b) preparing a solution with the anionic polysaccharide based on the stoichiometric charge ratio and adjusting to an acidic pH; (c) preparing a solution with the cationic polysaccharide based on the stoichiometric charge ratio and adjusting to an acidic pH; (d) adding the solution with the cationic polysaccharide to the solution with the anionic polysaccharide to obtain biodegradable colloidal particles; (e) reducing the particle size of the biodegradable colloidal particles; (f) separating the biodegradable colloidal particles from the supernatant; and (g) resuspending the biodegradable colloidal particles and storing them.

A biphasic nutraceutical system designed to deliver GRAS-certified bioactive compound families across two circadian-aligned phases: a daytime formulation supporting metabolic activation and cognitive readiness, and a nighttime formulation facilitating nutritional regeneration and immune balance. Active compounds are encapsulated respectively within phospholipid-stabilized micellar vesicles for sublingual delivery and pH-sensitive polysaccharide hydrogel matrices for delayed absorption. This dual-phase structure enables non-invasive, phase-specific release and enhances nutrient bioavailability without invoking pharmacological mechanisms. The system integrates principles of nutritional chronobiology and adaptive timing to synchronize absorption with physiological receptivity windows. Exclusively composed of GRAS-aligned functional ingredients, it supports general biological function under non-clinical conditions, remaining fully within the regulatory scope of dietary supplements under 21 CFR § 170.30.

The invention refers to standardized plant extract from biomass of in vitro cultures of Haberlea rhodopensis Friv. (HR), containing bioactive compounds and their primary secondary metabolites, containing in weight %, as follows: organic acid from 4.0 to 6.0, fatty acids from 0.5 to 1.5, amino acids from 8.0 to 12.0, sterols from 0.5 to 1.0, free phenols from 3.0 to 6.0, sugars from 45 to 55, and polyphenols from 25.0 to 35.0, with a predominant myconoside content of 70% to 96% in the polyphenolic fraction, constituting 18% to 35% of the total extract, and to a composition containing the standardized extract and glycerol as well as to a method for the preparation of a standardized plant extract.The method according this invention, along with its optimally chosen steps, specific conditions, parameters such as temperature, duration, stirring, light, growth factors, etc. achieves both maximum volumetric productivity of the target substances and myconoside, as well as stable productivity of the plant in vitro cultures and is a reliable efficient 24 / 7 continuous system for production of NPs.Dependence on natural factors, limited availability and protection of HR rare wild plant populations are eliminated. The limitations posed by seasonality and slow HR growth are also avoided by developing a renewable, ecologically method. The developed method provides alternative, renewable and sustainable sources of raw plant material necessary to obtain the target extract. The resulting extract standardized in myconoside is especially valuable with its protective action on human health and can successfully be used with its pharmacological, cosmetic effects as well as in functional foods.

The invention relates to the field of food pigments and functional ingredients, in particular to a method for extracting anthocyanin from aronia melanocarpa and application of the anthocyanin. According to the method, fresh aronia melanocarpa fruits are used as raw materials, the anthocyanin in the aronia melanocarpa is extracted through a water method and an enzyme method, and the conditions such as the temperature, the extraction time, the material-liquid ratio, the enzyme addition amount and the compound enzyme mass ratio in the extraction process are optimized. According to the extraction method, traditional knowledge and an innovative technology are combined, sustainable extraction of bioactive compounds is promoted, the anthocyanin rich in content can be extracted from the aronia melanocarpa, and the anthocyanin can be used for preparing functional ingredients such as drinks, foods and health care products. The invention not only provides an efficient and environment-friendly method for green extraction of the aronia melanocarpa anthocyanin, but also lays a scientific foundation for industrial production and application of the anthocyanin.

The present disclosure provides novel compositions for biologically active compounds that are administered through injection. The active compounds include, but are not limited to steroid hormones, diarylheptanoids, and flavonoids. These compositions are distinguished from the prior art through the addition of an oil to the overall composition, which results in a biphasic formulation. The oil serves to enhance the efficiency of delivery of the formulation to a human or animal subject, and reduces discomfort associated with the injection process. Optionally, one or more additional substances, each of which is soluble in oil, can be added to the oil to enable the deliverable of multiple active compounds in a single injection.

Methods for chemically modifying bioactive triterpene compounds to increase the bioavailability thereof. The resulting triterpene chemical compounds, having enhanced bioavailability, are useful in pharmaceutical compositions, alone, in combination with, or complexed with therapeutic drugs for the treatment of diseases such as cancers.

AI-BASED COMPUTER DEVICE FOR RAPID SCREENING OF BIOACTIVE COMPOUNDS IN MEDICINAL PLANTS

The present invention relates to efficient processes useful in the preparation of fluorinated nucleosides, such as (2S,3R,4S,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3-fluoro-4-hydroxy-2-(mercaptomethyl)tetrahydrofuran-3-yl dihydrogen phosphate, also known as 3′-fluoro-thio-guanosine monophosphate or 3′-F-thio-GMP. Such fluorinated nucleosides may be useful as a biologically active compound and or as an intermediate for the synthesis of more complex biologically active compounds. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation. (I)

Biostimulant compositions and methods for enhancing soil organic carbon are provided. A mixture of bioavailable B12 and amino acids phenylalanine (Phe) and lysine (Lys)—was found to enhance soil organic carbon and crop growth due to synergistic effects between the bioavailable B12 and the PheLys. The bioavailable B12 and the PheLys may be derived from various sources, including, e.g., cyanobacteria (e.g., Spirulina—Arthrospira platensis) or green algae (e.g., Nannochloropsis spp.) cultivated under photosynthetically controlled conditions to yield upregulated bio-active compounds such as bioavailable B12 and amino acids. One or more sources may be used to provide the bioavailable B12, Phe and Lys, and algal cultivation may be integrated with additional industries to yield synergistic biostimulation effects.

A composition is disclosed. The composition comprises one or more RNAs at least 95% identical to a bioactive milk-derived RNA selected from the group consisting of SEQ ID NOs 1-18. The disclosure also describes a process to generate stable milk RNA-rich extracts comprising SEQ ID 1-18 using natural milk (e.g., Bovine, human, or others), wherein the extract further comprises biologically active compounds. (e.g., nucleic acids molecules, oligosaccharides, proteins, and lipids). In some embodiments, the composition comprises one or more RNAs at least 100% identical to an RNA selected from the group consisting of SEQ ID NOs 1-18. In some embodiments, the composition comprises one or more RNAs at least 95%, 96%, 97%, 98%, or 99% identical to an RNA selected from the group consisting of SEQ ID NOs 1-18. In some embodiments, the composition comprises multiple RNAs.

This invention provides agricultural compositions and methods wherein plant health-promoting microbes are delivered on an improved granular carrier comprising milled plant parts and biological viability compounds that allows the microbes to remain stable at low moisture and to reproduce at high moisture.

The invention discloses an eyebrow pencil, and belongs to the field of cosmetics. The eyebrow pencil aims at solving the problem that an existing eyebrow pencil cannot give consideration to long-acting makeup keeping, smooth smearing and low irritation. The eyebrow pencil refill composition comprises a composite film forming system, a solvent and a solvent, wherein the composite film forming system is composed of polyesteride-5, trimethylsiloxy silicate and trimethyl pentaphenyl trisiloxane according to a specific weight ratio; the compound wax-based framework system is composed of ozokerite, oxidized polyethlene wax and Japanese wax; the specific skin feeling conditioning agent is a vinyl polydimethylsiloxane / polymethylsiloxane silsesquioxane cross-linked polymer; the plant-derived bioactive compound is prepared from herba centellae, herba portulacae and zanthoxylum piperitum fruit extracts; a colorant and a volatile solvent are also included. Through the synergistic effect of all the components, the eyebrow pencil has excellent water-proof, oil-proof, migration-resistant and makeup-keeping performance, excellent smearing smoothness, good mechanical strength and low irritation, is suitable for sensitive skin, is simple in preparation method and is suitable for industrial production.

This disclosure relates to synthetic methods of making bioactive in vivo precursors to plasmalogen compounds and salts thereof and to making plasmalogens and their derivatives and salts thereof. This disclosure also relates to chemical precursors to bioactive compounds and salts thereof. This disclosure further relates to compositions comprising one or more compounds of this disclosure and the use of such compositions in preparing compounds useful in methods of treating diseases and conditions that are beneficially treated by administering plasmalogens or their derivatives or precursors that are transformed in vivo to plasmalogens.

A disinfecting composition includes: one or more acetate-containing solvents in a total amount of from 0.1 to 20 wt. %; from 0.1 to 15 wt. % of hydrogen peroxide; and one or more biocidally active compounds in a total amount of from 0.1 to 10 wt. %; and wherein the disinfecting composition has a pH of from 0.5 to 3.5. The disinfecting composition was shown to have broad antimicrobial activity, including against bacteria and viruses, as well as to have excellent material compatibility.

A biphasic nutraceutical system designed to deliver GRAS-certified bioactive compound families across two circadian-aligned phases: a daytime formulation supporting metabolic activation and cognitive readiness, and a nighttime formulation facilitating nutritional regeneration and immune balance. Active compounds are encapsulated respectively within phospholipid-stabilized micellar vesicles for sublingual delivery and pH-sensitive polysaccharide hydrogel matrices for delayed absorption. This dual-phase structure enables non-invasive, phase-specific release and enhances nutrient bioavailability without invoking pharmacological mechanisms. The system integrates principles of nutritional chronobiology and adaptive timing to synchronize absorption with physiological receptivity windows. Exclusively composed of GRAS-aligned functional ingredients, it supports general biological function under non-clinical conditions, remaining fully within the regulatory scope of dietary supplements under 21 CFR §170.30.

Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I) or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L, L1, L2, L3, M, m and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.

Heterogeneous data may be received from one or more devices over a network. An image processor may analyze the image data to detect and classify one or more features. A data synthesizer may integrate the one or more features and associated classifications with remaining data to generate a health profile comprising one or more related biological, mental, emotional, and cognitive processes, such as those related to aging. The health profile may be monitored to identify temporal changes to predict an evolution of the health profile. A conditions correlator may correlate the evolution of the health profile to one or more health conditions. One or more Metabolites as Medicine ("MaM") models may identify one or more bioactive compounds to improve the one or more health conditions. The MaM models may analyze metabolic pathways in the human metabolome and predict effects of the bioactive compounds on the metabolic pathways.